Big news from the Center for AIDS Programme of Research in South Africa is being celebrated globally today. CAPRISA announced a breakthrough in research on male to female transmission of HIV with the use of vaginally applied tenofovir gel. With over 5 million people currently undergoing therapy for HIV/AIDS, and no cure in sight, prevention tactics are critical.
The results of the study were basically that using the gel cut a woman’s chances of getting HIV from her partner in half. This new drug is so important because it gives women the choice to protect themselves in cases where they do not know if their partner has HIV/AIDS or if their partner refuses to wear a condom. It is estimated that the gel will only cost 25 cents per dose, which is affordable enough to be widely marketed.
You can read more about the details of the study here.
The opinions expressed on the BUST blog are those of the authors themselves and do not necessarily reflect the position of BUST Magazine or its staff.